ACBP suppresses the proliferation, migration, and invasion of colorectal cancer via targeting Wnt/beta-catenin signaling pathway

Tong, Xin; Zhuang, Zhuochen; Wang, Xianjue; Yang, Xiaoyu; Bai, Liping; Su, Liya; Wei, Ping; Su, Xiulan

doi:10.1016/j.biopha.2020.111209

Cited by 15 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Abbreviated name Full official name Classification Intervention mechanism References 1 ACBP Anticancer bioactive peptide Novel bioactive peptide ACBP can inhibit phospho-LRP6 and stimulate phospho-β-catenin. [ 168 ] 2 ND MiR-377-3p MicroRNA Directly target ZEB2 and XIAP to inhibit Wnt/β-catenin signaling [ 169 ] 3 DHME Dehydroxyhispolon methyl ether Hispolon derivatives Inhibits β-catenin-mediated T cell factor (TCF)-dependent transcriptional activity [ 170 ] 4 ND SSTC3 New small molecule CK1α activator The target CK1α inhibits the growth of mouse CRC xenografts and attenuates the growth of patient-derived metastatic CRC xenografts [ 171 ] 5 CQD Chlorquinaldol Bacteriostatic agent Inhibit the acetylation of β-catenin, destroy the interaction between β-catenin and T cell factor 4 (TCF4), and reduce the binding of β-catenin to Wnt target gene promoters, and down-regulate the expression of these target genes [ 172 ] 6 ND KY7749 Compound Inhibit the proliferation and transformation of CRC cells, independently of β-catenin degradation of Ras [ 173 ] 7 ND Niclosamide Antihelminth compound Inhibit Wnt/β-catenin pathway activation, down-regulate Dvl2, and reduce downstream β-catenin signal transduction [ 174 ] 8 ND KHDRBS3 Genes encoding KH RNA binding domains, signal transduction related 3 KHDRBS3 may play a key role in acquiring stem cell characteristics (such as drug resistance and spheroid/organoid formation) by regulating the expression of CD44 variants and the Wnt signaling pathway [ 175 ] 9 ND KYA1797K ...…”

Section: Drugs and Inhibitorsmentioning

confidence: 99%

Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

et al. 2022

View full text Add to dashboard Cite

Background The Wnt signaling pathway is a complex network of protein interactions that functions most commonly in embryonic development and cancer, but is also involved in normal physiological processes in adults. The canonical Wnt signaling pathway regulates cell pluripotency and determines the differentiation fate of cells during development. The canonical Wnt signaling pathway (also known as the Wnt/β-catenin signaling pathway) is a recognized driver of colon cancer and one of the most representative signaling pathways. As a functional effector molecule of Wnt signaling, the modification and degradation of β-catenin are key events in the Wnt signaling pathway and the development and progression of colon cancer. Therefore, the Wnt signaling pathway plays an important role in the pathogenesis of diseases, especially the pathogenesis of colorectal cancer (CRC). Objective Inhibit the Wnt signaling pathway to explore the therapeutic targets of colorectal cancer. Methods Based on studying the Wnt pathway, master the biochemical processes related to the Wnt pathway, and analyze the relevant targets when drugs or inhibitors act on the Wnt pathway, to clarify the medication ideas of drugs or inhibitors for the treatment of diseases, especially colorectal cancer. Results Wnt signaling pathways include: Wnt/β-catenin or canonical Wnt signaling pathway, planar cell polarity (Wnt-PCP) pathway and Wnt-Ca2+ signaling pathway. The Wnt signaling pathway is closely related to cancer cell proliferation, stemness, apoptosis, autophagy, metabolism, inflammation and immunization, microenvironment, resistance, ion channel, heterogeneity, EMT/migration/invasion/metastasis. Drugs/phytochemicals and molecular preparations for the Wnt pathway of CRC treatment have now been developed. Wnt inhibitors are also commonly used clinically for the treatment of CRC. Conclusion The development of drugs/phytochemicals and molecular inhibitors targeting the Wnt pathway can effectively treat colorectal cancer clinically.

show abstract

Section: Drugs and Inhibitorsmentioning

confidence: 99%

Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These targets include functional oncogenes (160)(161)(162), epidermal growth factor-like proteins (163), adaptor proteins (4), stomatin-like proteins (164), chromatin organizers (165), antioxidants (166), and architectural transcription factors (105), which promote cRc growth via activating Wnt/β-catenin signaling. Additionally, negative regulatory targets inhibit cRc progression via inactivating Wnt/β-catenin signaling, and these targets include tumor suppressor genes (167,168), metastasis-suppressor genes (169), ubiquitin-like proteins (170) and anticancer bioactive peptides (171). In the present review, the effects of these therapy targets on cRc in the Wnt/β-catenin signaling pathway are presented in Table II (3,4,21,35,52,60,105,(160)(161)(162)(163)(164)(165)(166)(167)(168)(169)(170)(171)(172)(173)(174)(175)(176)(177)(178).…”

Section: Exogenous Modifier-associated Targetsmentioning

confidence: 99%

“…Additionally, negative regulatory targets inhibit cRc progression via inactivating Wnt/β-catenin signaling, and these targets include tumor suppressor genes (167,168), metastasis-suppressor genes (169), ubiquitin-like proteins (170) and anticancer bioactive peptides (171). In the present review, the effects of these therapy targets on cRc in the Wnt/β-catenin signaling pathway are presented in Table II (3,4,21,35,52,60,105,(160)(161)(162)(163)(164)(165)(166)(167)(168)(169)(170)(171)(172)(173)(174)(175)(176)(177)(178).…”

Section: Exogenous Modifier-associated Targetsmentioning

confidence: 99%

Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review)

Sun

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

colorectal cancer (cRc) is one of the most common carcinomas. Although great progress has been made in recent years, cRc survival remains unsatisfactory due to high metastasis and recurrence. Understanding the underlying molecular mechanisms of cRc tumorigenesis and metastasis has become increasingly important. Recently, aberrant Wnt/β-catenin signaling has been reported to be strongly associated with cRc tumorigenesis, metastasis and recurrence. Therefore, the Wnt/β-catenin signaling pathway has potential value as a therapeutic target for cRc. In the present review, the dysregulation of this pathway in cRc and the promoting or suppressing function of therapeutic targets on cRc were explored. In addition, the interaction between this pathway and epithelial-mesenchymal transition (EMT), cell stemness, mutations, metastasis-related genes and tumor angiogenesis in cRc cells were also investigated. Numerous studies on this pathway may help identify the potential diagnostic and prognostic markers and therapeutic targets for cRc. Contents1. Introduction 2. Role of Wnt/β-catenin signaling in colorectal cancer (cRc) 3. Therapeutic strategies targeting Wnt/β-catenin signaling for cRc 4. challenges in targeting Wnt/β-catenin signaling in cRc 5. conclusions and future perspectives

show abstract

“…Additionally, Wnt signaling pathway contributes to cancer cell growth and dissemination. Abnormal expression of Wnt signaling pathway can be observed in cancers [112][113][114][115][116][117]. Wnt/β-catenin signaling pathway can promote EMT through ZEB1 up-regulation to elevate the invasion and malignancy of tumor cells.…”

Section: Mirs As Modulators Of Zeb1mentioning

confidence: 99%

MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Molecular signaling pathways involved in cancer have been intensively studied due to their crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding homeobox-1 (ZEB1) and -2 (ZEB2) are molecules that play vital roles in signaling pathways to ensure the survival of tumor cells, particularly through enhancing cell proliferation, promoting cell migration and invasion, and triggering drug resistance. Importantly, ZEB proteins are regulated by microRNAs (miRs). In this review, we demonstrate the impact that miRs have on cancer therapy, through their targeting of ZEB proteins. MiRs are able to act as onco-suppressor factors and inhibit the malignancy of tumor cells through ZEB1/2 down-regulation. This can lead to an inhibition of epithelial-mesenchymal transition (EMT) mechanism, therefore reducing metastasis. Additionally, miRs are able to inhibit ZEB1/2-mediated drug resistance and immunosuppression. Additionally, we explore the upstream modulators of miRs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), as these regulators can influence the inhibitory effect of miRs on ZEB proteins and cancer progression.

show abstract

ACBP suppresses the proliferation, migration, and invasion of colorectal cancer via targeting Wnt/beta-catenin signaling pathway

Cited by 15 publications

References 30 publications

Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review)

MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Contact Info

Product

Resources

About